Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

SML2653

Sigma-Aldrich

Sorafenib

≥98% (HPLC), powder, kinase inhibitor

Sinônimo(s):

4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide, BAY 43-9006, BAY43-9006, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N′-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C21H16ClF3N4O3
Número CAS:
284461-73-0
Peso molecular:
464.82
Número MDL:
MFCD06411450
Código UNSPSC:
12352200
NACRES:
NA.77

Nome do produto

Sorafenib, ≥98% (HPLC)

Ensaio

≥98% (HPLC)

Formulário

powder

cor

white to beige

solubilidade

DMSO: 2 mg/mL, clear

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

FC(F)(F)c1c(ccc(c1)NC(=O)Nc2ccc(cc2)Oc3cc(ncc3)C(=O)NC)Cl

InChI

1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)

chave InChI

MLDQJTXFUGDVEO-UHFFFAOYSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Ações bioquímicas/fisiológicas

Sorafenib (BAY 43-9006) is an orally active kinase inhibitor that exerts broad-spectrum anticancer efficacy in vitro and in vivo via targeting b-Raf, c-Raf (Raf-1), as well as several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular endothelial growth factor receptors 2/3 (VEGFR-2/Flk-1/KDR, VEGFR-3), platelet-derived growth factor receptor-beta (PDGFR-ß), Flt-3, c-KIT, FGFR-1 (Flt-2) and RET.

Pictogramas

Health hazardEnvironment
GHS08,GHS09

Palavra indicadora

Danger

Frases de perigo

H360FD,H362,H372,H410

Classificações de perigo

Aquatic Acute 1 - Aquatic Chronic 1 - Lact. - Repr. 1B - STOT RE 1

Código de classe de armazenamento

6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 9

1 of 9

Erlotinib hydrochloride ≥98% (HPLC)

Sigma-Aldrich

SML2156

Erlotinib hydrochloride

Erastin ≥98% (HPLC)

Sigma-Aldrich

E7781

Erastin

Lapatinib ≥98% (HPLC)

Sigma-Aldrich

SML2259

Lapatinib

2,4,6-Tris(dimethylamino)-1,3,5-triazine 96%

Sigma-Aldrich

549835

2,4,6-Tris(dimethylamino)-1,3,5-triazine

Safranal ≥90%, stabilized

Sigma-Aldrich

W338907

Safranal

DL-Buthionine-(S,R)-sulfoximine

Sigma-Aldrich

B2640

DL-Buthionine-(S,R)-sulfoximine

Midostaurin hydrate ≥98% (HPLC), solid

Sigma-Aldrich

M1323

Midostaurin hydrate

FIN56 ≥98% (HPLC)

Sigma-Aldrich

SML1740

FIN56

Vinorelbine ditartrate salt hydrate ≥98% (HPLC), powder

Sigma-Aldrich

V2264

Vinorelbine ditartrate salt hydrate

Paul T C Wan et al.
Cell, 116(6), 855-867 (2004-03-24)
Over 30 mutations of the B-RAF gene associated with human cancers have been identified, the majority of which are located within the kinase domain. Here we show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal
Shengnan Liu et al.
Cancer letters, 453, 74-83 (2019-04-01)
Sorafenib has been used as a clinical targeted therapy for hepatocellular carcinoma (HCC) for more than a decade. In 2017, regorafenib was approved for HCC treatment and has since been reported to prolong the survival of advanced HCC patients after
Xudong Gao et al.
OncoTargets and therapy, 12, 1629-1640 (2019-03-19)
Hepatocellular carcinoma (HCC) is one of the heaviest malignant burdens in China. Molecular targeting agent, sorafenib, is the main therapeutic option for antitumor therapy of advanced HCC, but it is currently too expensive for the public and its therapeutic effect
Jeong-Ju Yoo et al.
International journal of molecular sciences, 20(6) (2019-03-17)
This study aimed to examine whether inhibition of hexokinase (HK)-II activity enhances the efficacy of sorafenib in in-vivo models of hepatocellular carcinoma (HCC), and to evaluate the prognostic implication of HK-II expression in patients with HCC. We used 3-bromopyruvate (3-BP)
Mater H Mahnashi et al.
Pharmaceuticals (Basel, Switzerland), 15(2) (2022-02-27)
Over the past few decades, the development of broad-spectrum anticancer agents with anti-angiogenic activity has witnessed considerable progress. In this study, a new series of pyrazolo[3,4-d]pyrimidines based on a phenylfuroxan scaffold were designed, synthesized, and evaluated, in terms of their
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica